|<  <<  <  Page 14 of 14  >  >>  >|    Search Page    Contents Page

Canada – Division 5 – Drugs for Clinical Trials

(2) The Minister shall suspend the authorization by sending to the sponsor a written notice of suspension of the authorization that indicates the effective date of the suspension, whether the authorization is suspended in its entirety or at a clinical trial site and the reason for the suspension.

(3) If the Minister has suspended an authorization, the Minister shall
(a) reinstate the authorization in its entirety or at a clinical trial site, as the case may be, if within 60 days after the effective date of the suspension the sponsor provides the Minister with information or documents that demonstrate that the situation giving rise to the suspension did not exist or that it has been corrected; or

(b) cancel the authorization in its entirety or at a clinical trial site, as the case may be, if within 60 days after the effective date of the suspension the sponsor has not provided the Minister with the information or documents referred to in paragraph (a).


|<  <<  <  Page 14 of 14  >  >>  >|    Search Page    Contents Page
© 2003-2018 First Clinical Research LLC.  Trademark Notice  Terms & Conditions  Privacy Statement  Site Map